61 related articles for article (PubMed ID: 33527812)
1. Ethambutol Optic Neuropathy: Vigilance and Screening, the Keys to Prevent Blindness with the Revised Anti-tuberculous Therapy Regimen.
Saxena R; Phuljhele S; Prakash A; Lodha R; Singh D; Karna S; Mohan A; Gandhi R; Menon V; Garg R; The Inosrg
J Assoc Physicians India; 2021 Feb; 69(2):54-57. PubMed ID: 33527812
[TBL] [Abstract][Full Text] [Related]
2. Hobson's choice - fixed drug combinations for tuberculosis and epidemic of ethambutol-induced optic neuropathy in India.
Dudani AI; Dudani AA; Dudani K; Dudani AA
Indian J Ophthalmol; 2024 Jan; 72(1):139. PubMed ID: 38131589
[No Abstract] [Full Text] [Related]
3. Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?
Kumar SR; Hissar SS; Ramesh PM; Shanmugam M; Kalaiselvan V; Prakash J; Padmapriyadarsini C
Int J Tuberc Lung Dis; 2024 Jan; 28(1):51-53. PubMed ID: 38178302
[No Abstract] [Full Text] [Related]
4. Ethambutol induced toxic optic neuropathy - A retrospective study in a tertiary eye care centre in Southern India.
Shanmugam MK; Sajja S; Kowsalya A; Balakrishnan HK; Jayasri KN
Nepal J Ophthalmol; 2022 Jul; 14(28):108-115. PubMed ID: 37609972
[TBL] [Abstract][Full Text] [Related]
5. Ethambutol-induced optic neuropathy.
Kyncl M; Fus M; Lestak J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Sep; 167(3):288-293. PubMed ID: 35582729
[TBL] [Abstract][Full Text] [Related]
6. Ethambutol and its ophthalmic effects; is screening and collaboration the new way forward?
Vyas A; Subramanyam A; Phatak S; Tiwari S
Indian J Tuberc; 2024 Jan; 71(1):30-34. PubMed ID: 38296388
[TBL] [Abstract][Full Text] [Related]
7. Potential underlying mechanisms of ethambutol induced optic neuropathy: Evidence from in vitro to clinical studies.
Kulniwatcharoen P; Hansapinyo L; Chattipakorn N; Chattipakorn SC
Food Chem Toxicol; 2023 Dec; 182():114176. PubMed ID: 37949203
[TBL] [Abstract][Full Text] [Related]
8. Visual fields in neuro-ophthalmology.
Kedar S; Ghate D; Corbett JJ
Indian J Ophthalmol; 2011; 59(2):103-9. PubMed ID: 21350279
[TBL] [Abstract][Full Text] [Related]
9. Visual Recovery Time in Patients with Ethambutol-induced Toxic Optic Neuropathy.
An HR; Lee BJ; Moon Y
Korean J Ophthalmol; 2024 Apr; 38(2):91-97. PubMed ID: 38351490
[TBL] [Abstract][Full Text] [Related]
10. Ethambutol and visual assessment in England: current practice and recommendations.
MacVinish S; McMaster D; Moledina T; Tamne SK; Ashworth J; Anderson SR
Eye (Lond); 2024 Jan; 38(1):112-117. PubMed ID: 37349548
[TBL] [Abstract][Full Text] [Related]
11. Optic neuropathy by ethambutol in a patient with multiple sclerosis.
Gómez-Calleja V; Pérez-García P; Ly-Yang F; Santos-Bueso E
Arch Soc Esp Oftalmol (Engl Ed); 2021 Feb; ():. PubMed ID: 33632567
[TBL] [Abstract][Full Text] [Related]
12. Atropine for the Treatment of Childhood Myopia in India: Multicentric Randomized Trial.
Saxena R; Dhiman R; Gupta V; Kumar P; Matalia J; Roy L; Swaminathan M; Phuljhele S; Velpandian T; Sharma N
Ophthalmology; 2021 Sep; 128(9):1367-1369. PubMed ID: 33545170
[No Abstract] [Full Text] [Related]
13. Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients.
Almaghrabi RS; Nizami I; Alameer R; Alshehri N; Almohaizeie A; Alrajhi AA; Omrani AS
Exp Clin Transplant; 2021 Apr; 19(4):359-366. PubMed ID: 33535940
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 cases.
Baluku JB; Bongomin F
Int J Infect Dis; 2021 Apr; 105():230-233. PubMed ID: 33610787
[TBL] [Abstract][Full Text] [Related]
15. Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg
Te Brake LHM; de Jager V; Narunsky K; Vanker N; Svensson EM; Phillips PPJ; Gillespie SH; Heinrich N; Hoelscher M; Dawson R; Diacon AH; Aarnoutse RE; Boeree MJ;
Eur Respir J; 2021 Jul; 58(1):. PubMed ID: 33542056
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
Trentalange A; Borgogno E; Motta I; Antonucci M; Pirriatore V; Costa C; Rossi G; Barco A; De Nicolò A; Piccioni P; D'Avolio A; Bonora S; Di Perri G; Calcagno A
Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
[TBL] [Abstract][Full Text] [Related]
17. N-Acetylcysteine treatment of neonatal acetaminophen toxicity caused by transplacental transfer - a case report.
McDougall G; Murphy NG; Loubani O
Clin Toxicol (Phila); 2021 Sep; 59(9):840-842. PubMed ID: 33527858
[TBL] [Abstract][Full Text] [Related]
18. Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.
Saxena R; Singh D; Phuljhele S; Kalaiselvan V; Karna S; Gandhi R; Prakash A; Lodha R; Mohan A; Menon V; Garg R
Indian J Ophthalmol; 2021 Dec; 69(12):3734-3739. PubMed ID: 34827033
[TBL] [Abstract][Full Text] [Related]
19. Ethambutol optic neuropathy in the extended anti-tubercular therapy regime: A systematic review.
Sabhapandit S; Gella V; Shireesha A; Thankachan L; Ismail M; Rao R; Talukdar R
Indian J Ophthalmol; 2023 Mar; 71(3):729-735. PubMed ID: 36872667
[TBL] [Abstract][Full Text] [Related]
20. Visual outcomes of toxic optic neuropathy secondary to Ethambutol: A retrospective observational study from India, an endemic country.
Ambika S; Lakshmi KP; Gopal M; Noronha OV
Indian J Ophthalmol; 2022 Sep; 70(9):3388-3392. PubMed ID: 36018127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
